杭州浙大迪迅生物基因工程有限公司Clinical Reviews：针对食物过敏的表皮免疫疗法（综述）
发布日期：2018-11-13
原标题：食物过敏表皮免疫治疗现状
延伸阅读
Clinical Reviews in Allergy & Immunology
DOI: org/10.1007/s12016-017-8650-3
Abstract:
The food allergy epidemic of recent years has led to the search for safe and effective methods of immunotherapy for foods. Studies of epicutaneous immunotherapy (EPIT) in mice have shown promising safety and efficacy data. Murine models have also identified probable mechanisms for the development of tolerance to food allergens, including the induction of regulatory T cells. Clinical data is lacking, but relatively small and early studies among peanut and cow’s milk allergic subjects suggest that EPIT has an excellent safety profile,particularly compared to other methods of specific allergen immunotherapy. Efficacy data are also promising for peanut allergy, among younger patients (ages 4–11 years of age),suggesting that a majority of young patients will experience an increase in reaction threshold with therapy. The goal of this therapy is the protection from accidental exposures to a known food allergen. Additional clinical data is needed to prove efficacy and further demonstrate the safety profile of EPIT for food allergy, prior to approval by the Food and Drug Administration.
First Author:
Bruce J. Lanser
Correspondence:
National Jewish Health
All Authors:
Bruce J. Lanser, Donald Y. M. Leung
——来自浙大迪迅
① 近年来食物过敏的流行导致急需寻找安全有效的免疫治疗方式；② 皮肤免疫治疗（EPIT）在小鼠中的研究得到了安全有效的数据；③ 小鼠模型还发现了一些可能对食物过敏原产生耐受性机制，包括调节性T细胞的诱导；④ 该方面研究目前缺乏临床资料，但在一些小型的早期研究表明，对于花生和牛奶的过敏患者，EPIT比其他特异性变应原免疫治疗方法更具有安全性；⑤ 该疗法的目的是防止意外暴露于已知的食物过敏原。
延伸阅读
Clinical Reviews in Allergy & Immunology
[IF:6.442]
The Current State of Epicutaneous Immunotherapy for Food Allergy: a Comprehensive ReviewDOI: org/10.1007/s12016-017-8650-3
Abstract:
The food allergy epidemic of recent years has led to the search for safe and effective methods of immunotherapy for foods. Studies of epicutaneous immunotherapy (EPIT) in mice have shown promising safety and efficacy data. Murine models have also identified probable mechanisms for the development of tolerance to food allergens, including the induction of regulatory T cells. Clinical data is lacking, but relatively small and early studies among peanut and cow’s milk allergic subjects suggest that EPIT has an excellent safety profile,particularly compared to other methods of specific allergen immunotherapy. Efficacy data are also promising for peanut allergy, among younger patients (ages 4–11 years of age),suggesting that a majority of young patients will experience an increase in reaction threshold with therapy. The goal of this therapy is the protection from accidental exposures to a known food allergen. Additional clinical data is needed to prove efficacy and further demonstrate the safety profile of EPIT for food allergy, prior to approval by the Food and Drug Administration.
First Author:
Bruce J. Lanser
Correspondence:
National Jewish Health
All Authors:
Bruce J. Lanser, Donald Y. M. Leung
2018-10-25 Review
创建过敏性疾病的科研、科普知识交流平台，为过敏患者提供专业诊断、治疗、预防的共享平台。
